http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-034550-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9008466a40998f8be8e54cd3aceb10a2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7064 |
| filingDate | 2013-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fb7590c6b90c3effccb288e2b0f7cb9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cee44aaa27f1b24a073267c00f40d5b0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7547cb13b69823a75750007469101bc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30425316768856a48b5536dade5ea165 |
| publicationDate | 2020-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-034550-B1 |
| titleOfInvention | METHODS FOR TREATING, REDUCING FREQUENCY AND / OR PREVENTION OF ISCHEMIC EVENTS |
| abstract | The invention relates to methods for treating, reducing the frequency and / or prophylaxis of an ischemic event in a patient undergoing percutaneous coronary angioplasty (PCI), comprising (1) administering an intravenous bolus injection of 30 μg kangrelor / kg before starting PCI; (2) continuous intravenous infusion of 4 μg / kg / min kangrelor after bolus administration; moreover, a continuous infusion of kangrelor continues for (a) at least 2 hours or (b) during the PCI; and (3) oral administration of a loading dose of ticagrelor in an amount of 180 mg (a) during a continuous infusion of kangrelor or (b) after the continuous infusion has been discontinued. The method may further include administering to the patient an additional therapeutic agent, wherein the additional therapeutic agent comprises a P2Y inhibitor. An ischemic event may include stent thrombosis, myocardial infarction, ischemic revascularization, and death. |
| priorityDate | 2013-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 185.